Evidence map›Paper›PMID 41182847›Full record

ArticleThe Journal of antimicrobial chemotherapy2025

Rifampicin as monotherapy for infections caused by Staphylococcus aureus: considerations for not applying 'breakpoints in brackets'.

Sara E Boyd, Mandy Wootton, Robin A Howe, David M Livermore, Alasdair P Macgowan, Gunnar Kahlmeter

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of antimicrobial chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sara E BoydDavid Price Evans Global Health and Infectious Disease Research Group, University of Liverpool, Institute of Systems, Molecular & Integrative Biology, William Henry Duncan Building, Liverpool L7 8TX, UK.ORCID 0000-0001-9935-5263
Mandy WoottonSpecialist Antimicrobial Chemotherapy Unit, Public Health Wales, University Hospital of Wales, Cardiff, UK.ORCID 0000-0002-2227-3355
Robin A HoweSpecialist Antimicrobial Chemotherapy Unit, Public Health Wales, University Hospital of Wales, Cardiff, UK.
David M LivermoreNorwich Medical School, University of East Anglia, Floor 2, Bob Champion Research & Educational Building, James Watson Road, Norwich NR4 7UQ, UK.
Alasdair P MacgowanAntimicrobial Reference Laboratory, North Bristol NHS Trust, Westbury-on Trym, Bristol, UK.
Gunnar KahlmeterClinical Microbiology, Central Hospital, 351 85 Växjö, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

EUCAST introduced 'breakpoints in brackets' to warn against the use of specified agents without additional therapeutic measures (EUCAST. Guidance document "EUCAST breakpoints in brackets". 2021. Available at: www.mic.eucast.org.). Rifampicin is rarely used as monotherapy for Staphylococcus aureus infections, yet its breakpoints remain unbracketed. Here, we explore whether this remains appropriate. Although frequent emergent resistance largely precludes rifampicin's use as monotherapy, this does not meet EUCAST's core criterion for bracketing-that an agent is inherently ineffective as monotherapy.

Indexed as

Anti-Bacterial AgentsRifampinStaphylococcal InfectionsStaphylococcus aureusDrug Resistance, BacterialHumansMicrobial Sensitivity TestsAnti-Bacterial AgentsRifampin

Identifiers

PMID41182847
PMCPMC12670147

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.